Otsuka Pharmaceutical Co., Ltd.

August 1, 2012

Vasopressin V2-Receptor Antagonist, Samsca® Tablets Were Filed Additional Indication of the Treatment of Fluid Retention Associated with Cirrhosis of the Liver

  • Application for additional indication as the world's first aquaretic treatment for water retention due to cirrhosis of the liver.
  • About one-third of the approximately 270,000 liver cirrhosis patients in Japan suffer from lifestyle interference due to fluid retention (swelling of the hands and feet; abdominal bloating).
  • An innovative, first-in-class treatment born from 27 years of research and development now being brought to 13 countries around the world.

Tokyo, Japan, July 31, 2012 -- Otsuka Pharmaceutical Co., Ltd. today announced that it applied in July to Japan's Ministry of Health, Labour and Welfare for an additional indication for Samsca® Tablets (tolvaptan), a V2-vasopressin receptor antagonist, as the world's first aquaretic treatment for fluid retention associated with cirrhosis of the liver.